PMID- 34372800
OWN - NLM
STAT- MEDLINE
DCOM- 20210811
LR  - 20210813
IS  - 1471-2482 (Electronic)
IS  - 1471-2482 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Aug 9
TI  - Prognostic value of preoperative body mass index for diabetic patients with 
      non-metastasis gastric cancer: a single center experience.
PG  - 320
LID - 10.1186/s12893-021-01316-x [doi]
LID - 320
AB  - AIM: This study was designed to investigate the prognostic effect of preoperative 
      body mass index (BMI) for Type 2 diabetes mellitus (T2DM) patients with 
      non-metastasis gastric cancer (GC) who underwent D(2) gastrectomy. METHODS: T2DM 
      patients with pT(1-4b)N(0-3b)M(0) GC were retrospectively collected in Department 
      of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital & Fujian Medical 
      University Cancer Hospital from January, 2000 to December, 2010. These patients 
      underwent D(2) radical resection of the stomach combined with regional 
      lymphadenectomy. Chi-square test was used to analyze unordered categorical 
      variables and ranked data, followed by Kaplan-Meier analysis as well as Cox 
      regression models to detect risk factors for survival outcomes. In addition, the 
      cut-off point was determined by the X-tile program. All analyses were carried out 
      using survival package of R and SPSS Software. RESULTS: A total of 302 T2DM 
      patients with pT(1-4b)N(0-3b)M(0) GC were collected and analyzed. The cut-off 
      points of BMI, identified by the X-tile program, was 19 kg/m(2). Patients with 
      low BMI (< 19 kg/m(2)) had a higher percentage of advanced T stage (T(4a) and 
      T(4b)), more advanced TNM stage (stage IIIA, IIIB and IIIC), and more elevated 
      level of serum carcinoembryonic antigen (CEA), compared to those with high BMI 
      (> 19 kg/m(2)) (all P < 0.05). In the low BMI subgroup, the 5-year overall 
      survival rate was 39.02%, which was as high as 58.11% in the high BMI subgroup 
      (P < 0.05). In the multivariate Cox regression model revealed that III(C) stage 
      (OR = 3.101), N(3b) stage (OR = 3.113) were the most important prognostic 
      indicators, followed by pretreatment BMI (OR = 2.136). CONCLUSION: Low 
      preoperative BMI (< 19 kg/m(2)) was a poor prognostic marker for T2DM patients 
      with pT(1-4b)N(0-3b)M(0) GC.
CI  - (c) 2021. The Author(s).
FAU - Ye, Zaisheng
AU  - Ye Z
AD  - Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital, and 
      Fujian Medical University Cancer Hospital, No. 420 Fu-ma Road, Jin-An District, 
      Fuzhou, 350014, China.
FAU - Wei, Shenghong
AU  - Wei S
AD  - Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital, and 
      Fujian Medical University Cancer Hospital, No. 420 Fu-ma Road, Jin-An District, 
      Fuzhou, 350014, China.
FAU - Zeng, Yi
AU  - Zeng Y
AD  - Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital, and 
      Fujian Medical University Cancer Hospital, No. 420 Fu-ma Road, Jin-An District, 
      Fuzhou, 350014, China.
FAU - Wang, Yi
AU  - Wang Y
AD  - Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital, and 
      Fujian Medical University Cancer Hospital, No. 420 Fu-ma Road, Jin-An District, 
      Fuzhou, 350014, China.
FAU - Lin, Zhitao
AU  - Lin Z
AD  - Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital, and 
      Fujian Medical University Cancer Hospital, No. 420 Fu-ma Road, Jin-An District, 
      Fuzhou, 350014, China.
FAU - Chen, Shu
AU  - Chen S
AD  - Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital, and 
      Fujian Medical University Cancer Hospital, No. 420 Fu-ma Road, Jin-An District, 
      Fuzhou, 350014, China.
FAU - Xie, Yunqing
AU  - Xie Y
AD  - Department of Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Cancer 
      Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian, 
      China.
FAU - Zheng, Qiuhong
AU  - Zheng Q
AD  - Department of Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Cancer 
      Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian, 
      China.
FAU - Chen, Luchuan
AU  - Chen L
AUID- ORCID: 0000-0003-3362-447X
AD  - Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital, and 
      Fujian Medical University Cancer Hospital, No. 420 Fu-ma Road, Jin-An District, 
      Fuzhou, 350014, China. luchuanchen@sina.cn.
LA  - eng
GR  - No. 2017J01264/National Science Foundation Project of Fujian Science and 
      Technology Department/
GR  - No. 2018Y0015/National Science Foundation Project of Fujian Science and 
      Technology Department/
GR  - No.2019-ZQN-16/Foundation for Fujian Provincial Health Technology Project/
GR  - 2019-CXB-9/Foundation for Fujian Provincial Health Technology Project/
GR  - 2019006/Foundation for Fujian Provincial Health Technology Project/
PT  - Journal Article
DEP - 20210809
PL  - England
TA  - BMC Surg
JT  - BMC surgery
JID - 100968567
SB  - IM
MH  - Body Mass Index
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Gastrectomy
MH  - Humans
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Retrospective Studies
MH  - *Stomach Neoplasms/complications/pathology/surgery
PMC - PMC8351091
OTO - NOTNLM
OT  - BMI
OT  - Gastric cancer
OT  - Survival rate
OT  - Type 2 diabetes mellitus
OT  - X-tile
COIS- The authors declare no conflicts of interest regarding this manuscript.
EDAT- 2021/08/11 06:00
MHDA- 2021/08/12 06:00
PMCR- 2021/08/09
CRDT- 2021/08/10 05:32
PHST- 2020/12/21 00:00 [received]
PHST- 2021/08/02 00:00 [accepted]
PHST- 2021/08/10 05:32 [entrez]
PHST- 2021/08/11 06:00 [pubmed]
PHST- 2021/08/12 06:00 [medline]
PHST- 2021/08/09 00:00 [pmc-release]
AID - 10.1186/s12893-021-01316-x [pii]
AID - 1316 [pii]
AID - 10.1186/s12893-021-01316-x [doi]
PST - epublish
SO  - BMC Surg. 2021 Aug 9;21(1):320. doi: 10.1186/s12893-021-01316-x.